It was further established, via a suite of laboratory testing, that DOT1L inhibition resulted in dysregulation of the cell cycle and cell death in MLL-fusion-driven leukemic cells as well as resensitisation to chemotherapy in other types of cancer (19, 25–27). The gene discussed is KMT2A; the disease is cancer.